Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.
about
A murine preclinical syngeneic transplantation model for breast cancer precision medicine.The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markersQuinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells.Integrating transcriptomics and proteomics to show that tanshinone IIA suppresses cell growth by blocking glucose metabolism in gastric cancer cells.Kinetic characterization of lactate dehydrogenase in normal and malignant human breast tissues.Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers.Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis.Isoform switch of pyruvate kinase M1 indeed occurs but not to pyruvate kinase M2 in human tumorigenesis.Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinomaGlobal analysis of protein folding thermodynamics for disease state characterizationAssociation of the Alu insertion polymorphism in the progesterone receptor gene with breast cancer in a Mexican population.Low Expression of LDHB Correlates With Unfavorable Survival in Hepatocellular Carcinoma: Strobe-Compliant Article.The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity.Serum lactate dehydrogenase and survival following cancer diagnosis.Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancerLDHB may be a significant predictor of poor prognosis in osteosarcoma.Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.Comprehensive landscape of subtype-specific coding and non-coding RNA transcripts in breast cancer.A platform for high-throughput bioenergy production phenotype characterization in single cells.The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.Subtyping of breast cancer using reverse phase protein arrays.Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance.Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype.The drs tumor suppressor regulates glucose metabolism via lactate dehydrogenase-B.Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens.A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients.Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer.
P2860
Q33580224-780182B1-A728-47CE-A75D-1D7B5A38762BQ34258373-394BFCF0-3096-4E85-A065-5A41EE4764B9Q34258961-1E4AA007-D9AF-42ED-891B-501D553DC1ACQ35083386-1A24EEF1-F950-48E8-9493-70DE40181A86Q35102776-1BFB1523-5245-4CD1-A38C-7CEE17C1BB8BQ35176109-6D368EB1-2A27-4630-B34F-C993738CC386Q35227377-80C95088-995E-4316-8F63-E5EE5A251AFCQ35571437-133EEFDF-E1BA-4CD8-BF27-CA354E4C5A29Q35606525-2CF4EB94-F311-432C-A809-8BB59A0E1FEAQ35678333-DD0ED724-DFC5-452A-BA83-D2E168EA83DFQ35829236-7BC35133-1CB5-4EE4-90CD-3BA178EF192CQ36195789-8B4C03B4-D37C-4404-84C4-C36A235C7BC9Q36710982-E76A6978-8EEE-4A71-AF2E-37B259B61252Q36750612-0300ED65-1864-4A6C-850E-48FC4154B60DQ37148936-01F8EECB-E11D-49FE-BC0A-CF9C0EFB04F6Q37448160-EC02D017-76D0-47C9-8734-8F65A1356890Q37618855-05C9FCCC-E4D9-4DDB-AC22-9438978FCEB6Q37704344-793C386D-1165-4582-A33E-292DC186C34CQ37708863-06014741-FE48-4AB0-84BA-733E90BE94E6Q37724045-E53B1068-87A1-4DFA-83C8-294EE32C00A0Q38190005-11AAF2F8-33DF-4A37-B6AD-86FE276CFC7FQ38268585-9EEC78E2-ED8F-4FBE-91D1-EEF1A8A7EE9DQ38741833-0B3ABE7D-5DA5-4C81-9576-A5E97C47BB74Q38895387-A0984B59-8163-4C4F-A205-3A5CF05B19B3Q38916543-F5D0C0AB-D8F5-4945-87DF-AFBD54672CDCQ47135858-06A88AAD-77B5-40AA-AB09-EDA3A0DABE49Q51684386-CBA518AD-3B83-4493-B6C1-96304CA0E1CCQ54976511-08EC8606-A0A3-443C-9DCF-7330FE347395
P2860
Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lactate dehydrogenase B: a met ...... chemotherapy in breast cancer.
@en
Lactate dehydrogenase B: a met ...... chemotherapy in breast cancer.
@nl
type
label
Lactate dehydrogenase B: a met ...... chemotherapy in breast cancer.
@en
Lactate dehydrogenase B: a met ...... chemotherapy in breast cancer.
@nl
prefLabel
Lactate dehydrogenase B: a met ...... chemotherapy in breast cancer.
@en
Lactate dehydrogenase B: a met ...... chemotherapy in breast cancer.
@nl
P2093
P2860
P1476
Lactate dehydrogenase B: a met ...... chemotherapy in breast cancer.
@en
P2093
Ana M González-Angulo
Carlos L Arteaga
Gordon B Mills
Henry L Gómez
Jennifer B Dennison
Jennifer R Molina
Joseph A Pinto
María G Kuba
Melinda E Sanders
Robert E Brown
P2860
P304
P356
10.1158/1078-0432.CCR-13-0623
P407
P577
2013-05-22T00:00:00Z